| abstract |
The invention generally relates to antibodies or antigen binding fragments that bind to human B and T lymphocyte attenuator (BTLA), and their use. More specifically, the invention relates to agonistic antibodies that bind to and regulate their activity in human BTLA, and their use in treating inflammatory, autoimmune and proliferative diseases and disorders. |